Trial Profile
A double-blind, crossover, placebo-controlled, multiple-dose study to evaluate the effects of vildagliptin on gastric emptying, gastric volume and satiety in patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 04 May 2012 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov record (NCT00351507).
- 04 May 2012 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov record (NCT00351507).
- 07 Aug 2009 Planned end date (Feb 2006) added as reported by ClinicalTrials.gov.